However, BRAF/NRAS-activating mutations are less frequently mutated in MM compared to CM [30]: 6% and 8%, respectively, versus 50% and 28% in CM, with a variable incidence depending on the anatomical district of melanoma occurrence [31]. This evidence concerns the gene NRAS and Miyoshi myopathy.